Form 4: Avanos Medical Director Receives Restricted Share Units

A Form 4 filing reveals that Julie Ann Shimer, a Director at Avanos Medical, Inc., was granted 12,003 restricted share units on May 8, 2026.

Summary

• Julie Ann Shimer, a Director at Avanos Medical, Inc. (AVNS), received 12,003 restricted share units (RSUs) on May 8, 2026.
• These RSUs are a replacement for previously issued RSUs from January 2, 2025.
• Each RSU represents a contingent right to receive a cash payment equivalent to the value of one share of Avanos Medical's common stock.
• The RSUs vest upon the Reporting Person's termination of service on the Issuer's Board of Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation adjustment for a director rather than a significant financial event or strategic shift.

Positives

• Director compensation in the form of equity-based awards, indicating alignment with long-term company performance.
• Grant of restricted share units suggests continued confidence in the company's future value by the board.

Negatives

• The RSUs are a replacement, which could imply a modification or adjustment to previous compensation arrangements, though the filing does not specify a reason.

Risks

• The value of the RSUs is tied to the future stock price of Avanos Medical, exposing the director to market volatility.
• Vesting is contingent on termination of board service, meaning the director may not realize the full value if they leave the board before vesting.

Future Outlook

The future outlook for the restricted share units is dependent on the future performance and stock price of Avanos Medical, Inc. The RSUs will vest upon the director's termination of service on the board.

Industry Context

StockSavvy.ai notes that the issuance of restricted share units to directors is a common practice in the healthcare and medical technology industry to incentivize long-term performance and align executive interests with shareholders.

Stakeholder Impact

• Shareholders: The issuance of RSUs represents a form of compensation, which impacts dilution and executive compensation structures. The replacement nature of the grant may warrant further inquiry into the reasons behind the adjustment.
• Directors: The director receives equity-based compensation, aligning their interests with the company's long-term stock performance.

Next Steps

• The restricted share units will vest upon the Reporting Person's termination of service on the Issuer's Board of Directors.

Key Dates

Keywords

Form 4, SEC Filing, Avanos Medical, AVNS, Director Compensation, Restricted Share Units, Equity Awards, Insider Transaction